Publications
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916
Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood advances. 2025. PMID: 40334068
Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood advances. 2025. PMID: 40334068
Phi LTH, Cheng Y, Funakoshi Y, Bertucci F, Finetti P, Van Laere SJ, Zou F, Long JP, Ogata S, Krishnamurthy S, Reuben JM, Foulks JM, Warner SL, Rosenbluth JM, Sood AK, Tripathy D, Ueno NT, Wang X. AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization. Breast cancer research : BCR. 2025. PMID: 40329335
Chi KN, Castro E, Attard G, Smith MR, Sandhu S, Efstathiou E, Roubaud G, Small EJ, de Santana Gomes AP, Rathkopf DE, Saad M, Gurney H, Jung W, Kim W, Dibaj S, Wu D, Zhang J, Lopez-Gitlitz A, Francis P, Olmos D. Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. European urology oncology. 2025. PMID: 40328571
Schibler B, Spinner M, Naqvi IA, Stein J, Barbuto S. Developing an intensive aerobic exercise program after stroke: A pilot study. PM & R : the journal of injury, function, and rehabilitation. 2025. PMID: 40317613
Pan D, Mouhieddine TH, Sheng T, Fu W, Moshier E, Richter J, Parekh S, Jagannath S, Rossi AC, Sanchez LJ, Thibaud S, Rodriguez C, Cho HJ, Richard S. Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma. Bone marrow transplantation. 2025. PMID: 40319194
Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast (Edinburgh, Scotland). 2025. PMID: 40344957
Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE, Parikh RA. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40315400
Casey M, Tozzi F, Wang J, Park KM, Bergsland E, Hope T, Kennecke HF, Rose JB, Babicky M, Irani SS, El-Hayek KM, Hilal MA, Asbun HJ, Cleary S, Smeets P, Berrevoet F, Adam M, Rashidian N, Alseidi A, PNET Diagnosis Research Group. Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus. Surgical endoscopy. 2025. PMID: 40316747
Castellanos CX, Lin ME, Gallagher TJ, Swanson MS, Kwon DI. Surgeon Perspectives on Addressing Mental Health Among Total Laryngectomy Patients. Psycho-oncology. 2025. PMID: 40281582
Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Carrillo RB, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO open. 2025. PMID: 40315659